Evidence map›Paper›PMID 29273355›Full record

ArticleEBioMedicine2018

What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM.

M Bendenoun, A Samri, V Avettand-Fènoël, S Cardinaud, B Descours, G Carcelain, M-C Mazeron, J-F Bergmann, A Urrutia, A Moris and 10 more

Abstract read
In one paragraph

Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

M BendenounDépartement de Médecine Interne, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France.
A SamriU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France.
V Avettand-FènoëlEA7327, Faculté de Médecine, Université Paris-Descartes, Sorbonne Paris Cité, France; Laboratoire de Virologie, Hôpital Necker-Enfants Malades, APHP, Paris, France.
S CardinaudU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France.
B DescoursU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France.
G CarcelainU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France; Département d'Immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
M-C MazeronLaboratoire de Virologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France.
J-F BergmannDépartement de Médecine Interne, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France.
A UrrutiaU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France.
A MorisU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France; Département d'Immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
C RouziouxEA7327, Faculté de Médecine, Université Paris-Descartes, Sorbonne Paris Cité, France; Laboratoire de Virologie, Hôpital Necker-Enfants Malades, APHP, Paris, France.
F SimonLaboratoire de Virologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France.
P AndreCIRI, INSERM U1111, CNRS UMR5308, Université Lyon 1, ENS de Lyon, Lyon, France; Laboratoire de Virologie, Hôpital de la Croix-Rousse, Lyon, France.
M PocardService de Chirurgie Digestive et Cancérologique, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France; INSERMU 965, Angiogenèse et recherche translationnelle, Paris 7, France.
X DrayService de Gastroentérologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France.
T MourezNormandie Univ, UNIROUEN, EA 2656, Rouen University Hospital, Department of Virology, F-76000 Rouen, France.
V VieillardU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France; CNRS ERL8255, Centre, d'Immunologie et de Maladies Infectieuses (CIMI-Paris), Paris, France.
B AutranU1135, CIMI, INSERM, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France; Département d'Immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
F BarinInserm U966 & National Reference Center for HIV, Université François-Rabelais & CHU Bretonneau, Tours, France.
P SellierDépartement de Médecine Interne, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France. Electronic address: pierre.sellier@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe describe a homosexual man who strongly controlled HIV-1 for ten years despite lack of protective genetic background.

methodsHIV-1 DNA was measured in blood and other tissues. Cell susceptibility was evaluated with various strains. HIV-1-specific (CD4 and CD8 activation markers and immune check points) and NK cells responses were assessed; KIRs haplotypes and HLA alleles were determined.

findingsTwo HIV-1 RNA copies/mL of plasma were detected in 2009, using an ultra-sensitive assay. HIV-DNA was detected at 1.1 and 2 copies/10

interpretationThis thorough description of the natural history of an individual controlling HIV-1 in various compartments for ten years despite lack of protective alleles, and of his partner, may have implications for strategies to cure HIV-1 infection.

Indexed as

Genetic BackgroundSexual PartnersAdultHIV-1HIV InfectionsHomosexuality, MaleHumansMalePhylogenyT-LymphocytesElite controlHIV-1HIV-1 DNAHLA B*07 C*07Immune activationIncomplete western blotPartner

Identifiers

PMID29273355
PMCPMC5828297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.